ROCKVILLE, Md., March 16 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the issuance of U.S. Patent No. 7,012,070 covering methods of treatment for a broad range of indications with its lead clinical-stage compound, 2-methoxyestradiol (2ME2). Panzem(R) NCD, an oral formulation of 2ME2, is currently in Phase 2 clinical trials for cancer. Panzem(R) is also in preclinical development for rheumatoid arthritis.
(Logo: Newscom: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )
Patent No. 7,012,070, entitled “Estrogenic Compounds as Anti-Mitotic Agents,” contains claims granted by the U.S. Patent Office covering 2ME2 for the treatment of multiple indications, including cancer and inflammatory disorders such as rheumatoid arthritis. The patent claims cover methods of treating a broad range of disease indications with 2ME2 that is independent of mechanism, including solid tumors or tumor metastases, immune and inflammatory diseases, including rheumatoid arthritis. The patent is owned by Children’s Hospital Boston and licensed exclusively worldwide to EntreMed, Inc.
Panzem(R) (2ME2) is a novel anticancer agent, which is part of a next generation of antimitotic cancer drugs that bind to tubulin and work through multiple cellular pathways. 2ME2 can attack tumors on multiple fronts -- directly by disrupting microtubules, an intracellular matrix necessary for the rapid division of cancer cells (mitosis), by inducing programmed cell death (apoptosis), and by blocking blood vessels that feed tumors (angiogenesis inhibition).
Angiogenesis is also an integral component of the rheumatoid arthritis (RA) disease process. Results from preclinical studies support the potential for 2ME2 as a disease modifying anti-rheumatic drug (DMARD). Antiarthritic activities of 2ME2 were observed in both preventive (prior to arthritis onset) and treatment studies (active arthritis). When 2ME2 was administered in the preventive setting, the onset of arthritis was delayed significantly. When 2ME2 was administered in the disease treatment setting, there was marked inhibition of tissue and joint damage. The beneficial effects of 2ME2 in RA models were dose-dependent and non-immunosuppressive.
James S. Burns, EntreMed President & CEO, commented, “EntreMed is focused on the development of a new generation of small molecule drugs for the treatment of cancer and inflammatory disorders by attacking disease cells directly and the blood vessels that nourish them. This patent further expands our intellectual property coverage for 2ME2, our lead multi-mechanism drug candidate currently in Phase 2 clinical trials for cancer.”
Mr. Burns further commented, “We have increasing evidence that 2ME2 has both antitumor and antiinflammatory properties, providing us with potential opportunities to treat cancer and rheumatoid arthritis. We are committed to developing a strong intellectual property position for this compound based on a portfolio of composition, method, use and formulation patents.”
About EntreMed
EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) (2-methoxyestradiol or 2ME2), the Company’s lead drug candidate, is currently in Phase 2 clinical trials for cancer, as well as in preclinical development for rheumatoid arthritis. MKC-1, recently acquired through the Company’s acquisition of Miikana Therapeutics, is also in Phase 2 studies for cancer. EntreMed’s goal is to develop and commercialize new compounds based on the Company’s expertise in angiogenesis, cell cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company’s website at http://www.entremed.com and in various filings with the Securities and Exchange Commission.
Forward Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under “Risk Factors,” including risks relating to: the need for additional capital and the uncertainty of additional funding; the integration of Miikana and its product candidates; the early stage of our products under development; that results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; our dependence on third parties; and regulatory risks.
CONTACT: Ginny Dunn, Associate Director, Corporate Communications & Investor Relations of EntreMed, Inc., +1-240-864-2643
Photo: Newscom: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk photodesk@prnewswire.comEntreMed, Inc.
CONTACT: Ginny Dunn, Associate Director, Corporate Communications &Investor Relations of EntreMed, Inc., +1-240-864-2643
Web site: http://www.entremed.com//
